Cargando…

TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription

The existence of breast cancer stem cells (BCSCs) is a major reason underlying cancer metastasis and recurrence after chemotherapy and radiotherapy. Targeting BCSCs may ameliorate breast cancer relapse and therapy resistance. Here we report that expression of the pseudokinase Tribble 3 (TRIB3) posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jin-mei, Sun, Wei, Wang, Zhen-he, Liang, Xiao, Hua, Fang, Li, Ke, Lv, Xiao-xi, Zhang, Xiao-wei, Liu, Yu-ying, Yu, Jiao-jiao, Liu, Shan-shan, Shang, Shuang, Wang, Feng, Yang, Zhao-na, Zhao, Chen-xi, Hou, Xue-ying, Li, Ping-ping, Huang, Bo, Cui, Bing, Hu, Zhuo-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915745/
https://www.ncbi.nlm.nih.gov/pubmed/31844113
http://dx.doi.org/10.1038/s41467-019-13700-6
Descripción
Sumario:The existence of breast cancer stem cells (BCSCs) is a major reason underlying cancer metastasis and recurrence after chemotherapy and radiotherapy. Targeting BCSCs may ameliorate breast cancer relapse and therapy resistance. Here we report that expression of the pseudokinase Tribble 3 (TRIB3) positively associates with breast cancer stemness and progression. Elevated TRIB3 expression supports BCSCs by interacting with AKT to interfere with the FOXO1-AKT interaction and suppress FOXO1 phosphorylation, ubiquitination, and degradation by E3 ligases SKP2 and NEDD4L. The accumulated FOXO1 promotes transcriptional expression of SOX2, a transcriptional factor for cancer stemness, which in turn, activates FOXO1 transcription and forms a positive regulatory loop. Disturbing the TRIB3-AKT interaction suppresses BCSCs by accelerating FOXO1 degradation and reducing SOX2 expression in mouse models of breast cancer. Our study provides insights into breast cancer development and confers a potential therapeutic strategy against TRIB3-overexpressed breast cancer.